Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease

Molecular Medicine

Volumn 13, Issue 9-10, 2007, Pages 542-550

  Bellucci, Catia ^a   Lilli, Cinzia ^a   Baroni, Tiziano ^a   Parnetti, Lucilla ^a   Sorbi, Sandro ^b   Emiliani, Carla ^a   Lumare, Eleonora ^a   Calabresi, Paolo ^a   Balloni, Stefania ^a   Bodo, Maria ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PROTEOGLYCAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FAMILIAL DISEASE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST;

ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; COLLAGEN; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; GENE EXPRESSION; GLYCOSAMINOGLYCANS; HUMANS; MATRIX METALLOPROTEINASE 1; PROTEOGLYCANS; RNA, MESSENGER; SKIN;

EID: 35348888450     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00034.Bellucci     Document Type: Article

References (69)

1. Smith MA. (1998) Alzheimer disease. Int. Rev. Neurobiol. 42:1-54.
2. Hardy J. (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:154-9.
3. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. (1997) Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation, and maintains Aβ fibril stability. J. Neurochem. 69:2452-65.
4. Bruckner G, Hausen D, Harting W, Drlicek M, Arendt T, Brauer K. (1999) Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected by cytoskeletal changes in Alzheimer's disease. Neuroscience 92:791-805.
5. Gerst JL et al. (2000) Altered cell-matrix associated ADAM proteins in Alzheimer disease. J. Neurose. Res. 59:680-4.
6. Ge YW, Lahiri DK. (2002) Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. Ann. N. Y. Acad. Sci. 973:463-7.
7. Gilad GM, Kagan HM, Gilad VH. (2005) Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain. Neurosci. Lett. 376:210-4.
8. Monning U, Sandbrink R, Weidemann A, Banati RB, Masters CL, Beyreuther K. (1995) Extracellular matrix influences the biogenesis of amyloid precursor protein in microglial cells. J. Biol. Chem. 270:7104-10.
9. Berzin TM et al. (2000) Agrin and microvascular damage in Alzheimer's disease. Neurobiol. Aging. 21:349-55.
10. Van Horssen J et al. (2002) Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer's disease brains. Brain Pathol. 12:456-62.
11. Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K. (1994) Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am. J. Pathol. 144:337-47.
12. Snow AD et al.(1995) Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin and versican) to the beta amyloid protein of Alzheimer's disease. Arch. Biochem. Biophys. 320:84-95.
13. Snow AD, Wight TN. (1989) Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging. 10:481-97.
14. DeWitt DA, Silver J, Canning DR, Perry G. (1993) Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp. Neurol. 121:149-52.
15. Snow AD, Castillo GM. (1997) Specific proteoglycans as potential causative agents and relevant targets for therapeutic intervention in Alzheimer's disease and other amyloidoses. Amyloid: Int. J. Exp. Clin. Invest. 4:135-41.
16. Mattson MP et al. (1997) Cellular signaling roles of TGFβ, TNFα, and βAPP in brain injury responses and Alzheimer's disease. Brain Res. Rev. 23:47-61
17. Griffin WS et al. (1998) Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. Brain Pathol. 8:65-72.
18. Satoh J, Kuroda Y. (2000) Amyloid precursor proteinβ-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. Neuropathology. 20; 289-96.
19. Eckenstein FP. (1994) Fibroblast growth factors in the nervous system. J. Neurobiol. 25:1467-80.
20. Eckenstein FP, Andersson C, Kuzis K, Woodward WR. (1994) Distribution of acidic and basic fibroblast growth factors in the mature, injured and developing rat nervous system. Prog. Brain Res. 103:55-64.
21. Reier PJ, Houle J. (1988). The glial scar: its bearing on axonal elongation and transplantation approaches to CNS repair. Adv. Neurol. 47:87-138.
22. Ecklancher F, Kehrli P, Labourdette G, Sensenbrenner M. (1996) Basic fibroblast growth factor (bFGF) injection activates the glial reaction in the injured adult rat brain. Brain Res. 737:201-14.
23. Kuzis K, Reed S, Cherry NJ, Woodward WR, Eckenstein FP (1995) Developmental time course of acidic and basic fibroblast growth factors' expression in distinct cellular populations of the rat central nervous system. J. Comp. Neurol. 358: 142-53.
24. Johnson DE, Williams LT. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60:1-41.
25. Stopa EG et al. (1990) Basic fibroblast growth factor in Alzheimer's disease. Biochem. Biophys. Res. Commun. 171:690-6.
26. Lahiri DK, Nall C. (1995) Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res. Mol. Brain Res. 32:233-40.
27. Perry G et al. (1991) Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease. J. Neurosci. 11:3679-83.
28. Matsumoto A, Fujiwara Y. (1993) Aberrant proteolysis of the β-amyloid precursor protein in familial Alzheimer's disease lympho-blastoid cells. Eur. J. Biochem. 217:21-7.
29. Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T. (1999) Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at Abeta40 and Abeta42. Neuroreport. 10:2965-9.
30. Horiguchi Y, Fine JD, Leigh IM, Yoshiki T, Ueda M, Imamura S. (1992) Lamina densa malformation involved in histogenesis of primary localized cutaneous amyloidosis. J. Invest. Dermatol. 99:12-8.
31. Schultz RT, Pitha J. (1985) Relation of the hepatic and splenic microcirculations to the development of lesions in experimental amyloidosis. Am. J. Pathol. 119:127-37.
32. Young ID, Willmer JP, Kisilevsky RT. (1989) The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis. Acta Neuropathol. 78:202-9.
33. Czech C, Tremp G, Pradier L. (2000) Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. Prog. Neurobiol. 60:363-84.
34. Hardy J, Selkoe DJ. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353-6.
35. De Strooper B. (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 38:9-12.
36. Thinakaran G, Parent AT. (2004) Identification of the role of presenilins beyond Alzheimer's disease. Pharmacol. Res. 50:411-8.
37. Bertram L et al. (2005) Family-based association between Alzheimer's disease and variants in UBQLN1. N. Engl. J. Med. 352:884-94.
38. Li D et al. (2006) Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am. J. Hum. Genet. 79:1030-9.
39. Uberti D et al. (2002) Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. J. Cell Sci. 115: 3131-8.
40. Trippi F et al. (2001) Spontaneous and induced chromosome damage in somatic cells of sporadic and familial Alzheimer's disease patients. Mutagenesis. 16:323-7.
41. Emiliani C et al. (2003) Up-regulation of glycohydrolases in Alzheimer's disease fibroblasts correlates with Ras activation. J. Biol. Chem. 278:38453-60.
42. Cecchi C et al. (2007) Increased susceptibility to amyloid toxicity in familial Alzheimer's fibroblasts. Neurobiol. Aging. 28:863-76.
43. Conrad GW, Hamilton C, Haynes E. (1977) Differences in glycosaminoglycans synthesized by fibroblast-like cells from chick cornea, heart, and skin. J. Biol. Chem. 252:6861-70.
44. Webster DF, Harvey W. (1979) A quantitative assay for collagen synthesis in microwell fibroblasts cultures. Anal. Biochem. 96:220-4.
45. Moscatelli D. (1987) High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J. Cell Physiol. 131:123-30.
46. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to his high affinity receptor. Cell. 64:841-8.
47. Scatchard G. (1949) The attractions of proteins for small molecules and ions. Ann. NY Acad. Science. 51:660-72.
48. Magnus JH, Stenstad T. (1997) Proteoglycans and the extracellular matrix in amyloidosis. Amyloid: Int. J. Exp. Clin. Invest. 4:121-34.
49. Deininger MH, Fimmen BA, Thal DR, Schluesener HJ, Meyermann R. (2002) Aberrant neuronal and paracellular deposition of endostatin in brains of patients with Alzheimer's disease. J. Neuroscience. 22:10621-6.
50. Narindrasorasak S, Lowery DE, Altman RA, Gonzales DP, Greenberg B, Kisilevsky R. (1992) Characterization of high affinity binding between laminin and Alzheimer's disease amyloid precursor proteins. Lab. Invest. 67:643-52.
51. Matsumoto A, Enomoto T, Fujiwara Y, Baba H, Matsumoto R. (1996) Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain. Neurosc. Lett. 220:159-62
52. Cecchi C et al. (1999) Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neurosci. Lett. 275:152-4.
53. Bagnoli S et al. (2002) Cathepsin D polymorphism in Italian sporadic and familial Alzheimer's disease. Neurosci. Lett. 328:273-6.
54. Fillit H, Leveugle B. (1995) Disorders of the extracellular matrix and the pathogenesis of senile dementia of the Alzheimer's type. Lab. Invest. 72:249-53.
55. Kahari VM, Larjava H, Uitto J. (1991) Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. J. Biol. Chem. 266:10608-15.
56. Stichel CC, Kappler J, Junghans U, Koops A, Kresse H, Muller HW. (1995) Differential expression of the small chondroitin/dermatan sulfate proteoglycans decorin and biglycan after injury of the adult rat brain. Brain Res, 704:263-74.
57. Cosgaya JM, Latasa MJ, Pascual A. (1996) Nerve growth factor and ras regulate beta-amyloid precursor protein gene expression in PC12 cells. J. Neurochem. 67:98-104.
58. Abe K, Saito H. (2001) Effects of basic fibroblast growth factor on central nervous system functions. Pharmacol. Res. 43:307-12.
59. Furukawa K, Fu W, Li Y, Witke W, Kwiatkowski DJ, Mattson MP. (1997) The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons. J. Neurosci. 17: 8178-86.
60. Thorns V, Masliah E, (1999) Evidence for neuroprotective effects of acidic fibroblast growth factor in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58:296-306.
61. Masliah E et al. (1997) Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience. 78:135-46.
62. Guo Q et al. (1999) Neurotrophic factors (activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)) interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. U. S. A, 96: 4125-30.
63. Tsukamoto E, Hashimoto Y, Kanekura K, Niikura T, Aiso S, Nishimoto I. (2003) Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. J. Neurosci. Res. 73:627-36.
64. Mosconi L et al. (2003) Brain metabolic differ-ences between sporadic and familial Alzheimer's disease. Neurology. 61:1138-40.
65. Flint N, Cove FL, Evans GS. (1994) Heparin stimulates the proliferation of intestinal epithelial cells in primary culture. J. Cell Sci. 107:401-11.
66. Klagsbrun M, Baird A. (1991) A dual receptor system is required for basic fibroblast growth factor activity. Cell. 67:229-31.
67. Aviezer D et al. (1994) Differential structural requirements of heparin and heparin sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J. Biol. Chem. 269:114-21.
68. Leveugle B et al. (1997) Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursorprotein. Neurochem. Int. 30:543-8.
69. Leveugle B et al. (1998) Heparin oligosaccharides that pass the blood-brain barrier inhibit β-amyloid precursor protein secretion and heparin binding to β-amyloid peptide. J. Neurochem. 70:736-44.